Synthetic lethality of cyclin-dependent kinase inhibitor Dinaciclib with VHL-deficiency allows for selective targeting of clear cell renal cell carcinoma

por Nelson, Luke J, Castro, Kyleen E, Xu, Binzhi, Li, Junyi, Dinh, Nguyen B, Thompson, Jordan M, Woytash, Jordan, Kipp, Kevin R, Razorenova, Olga V
Publicado 2022

A mitochondrial unfolded protein response inhibitor suppresses prostate cancer growth in mice via HSP60

por Kumar, Rahul, Chaudhary, Ajay K., Woytash, Jordan, Inigo, Joseph R., Gokhale, Abhiram A., Bshara, Wiam, Attwood, Kristopher, Wang, Jianmin, Spernyak, Joseph A., Rath, Eva, Yadav, Neelu, Haller, Dirk, Goodrich, David W., Tang, Dean G., Chandra, Dhyan
Publicado 2022